biology-products/dako-target-retrieval-solution--citrate-ph-6--28x-10-29-from-dako-1601-1/;msg90356

Breaking Biology Technology:YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2 YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3 YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3

[0] YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT [0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner

Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2 AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2 AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3 Tamiflu Resistant Swine Flu Passed Person to Person in U S 60332 1 Tamiflu Resistant Swine Flu Passed Person to Person in U S 60332 2 Tamiflu Resistant Swine Flu Passed Person to Person in U S 60332 3 Tamiflu Resistant Swine Flu Passed Person to Person in U S 60332 4 Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois 60329 1 Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois 60329 2 Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois 60329 3 VetsFirst Established by United Spinal Association 3A First and Only Organization to Offer Full Membership to All Disabled Veterans Their Dependents 60326 1 VetsFirst Established by United Spinal Association 3A First and Only Organization to Offer Full Membership to All Disabled Veterans Their Dependents 60326 2

[0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies [0] AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens